Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared post on X about a recent paper by Roberto Borea et al. published in Critical Reviews in Oncology/Hematology:
“Cancer in a drop: Liquid biopsy reached a scientific peak in 2024.
ctDNA remains the star analyte for early detection, MRD, resistance, and treatment guidance.
AI is enhancing sensitivity, and non-blood fluids are gaining ground.
A new era in precision oncology.”
Title: Cancer in a drop: Advances in liquid biopsy in 2024
Journal: Critical Reviews in Oncology/Hematology
Authors: Roberto Borea, Erick F. Saldanha, Shivahamy Maheswaran, Eleonora Nicolo, Surbhi Singhal, Letizia Pontolillo, Diego de Miguel Perez, Konstantinos Venetis, Angelo Dipasquale, Nadia Ghazali, Pasquale Pisapia, Ana Ortega Franco, Mohamed A. Gouda, Carolina Reduzzi
More posts featuring Diego A. Díaz García on OncoDaily.
